<DOC>
	<DOCNO>NCT01967862</DOCNO>
	<brief_summary>This phase II trial study well fluorine F 18 sodium fluoride positron emission tomography ( PET ) /computed tomography ( CT ) whole body axial magnetic resonance imaging ( MRI ) work find metastasis patient recurrent prostate cancer . New image technique , fluorine F 18 sodium fluoride PET/CT whole body axial MRI , may effective standard CT bone scan finding metastatic prostate cancer .</brief_summary>
	<brief_title>Fluorine F 18 Sodium Fluoride PET/CT Whole Body Axial MRI Finding Metastases Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine proportion patient biochemically-recurrent prostate cancer ( PC ) image whole body ( WB ) /axial MRI F-18 NaF ( fluorine F 18 sodium fluoride ) PET/CT result detection metastatic disease visualize CT scan bone scan . SECONDARY OBJECTIVES : I . To estimate percent eligible patient negative , indeterminate positive CT scan/bone scan target X-rays do . II . To determine proportion patient biochemically-recurrent PC recurrence prostate bed visualized use MRI absence detection use CT scan . III . To correlate presence metastatic disease detect use WB/axial MRI and/or F-18 NaF PET/CT predict 6-year probability progression-free survival base Memorial Sloan Kettering Cancer Center salvage radiation therapy ( RT ) PC nomogram , prostate-specific antigen ( PSA ) level baseline . IV . To compare role axial MRI spine WB/axial MRI respect ability identify site disease . Similarly , evaluate relative contribution F-18 NaF PET WB/axial MRI . OUTLINE : Patients first undergo CT scan bone scan . Patients negative result CT bone scan undergo WB MRI scan use diffusion-weighted MRI , axial MRI scan use 3-Tesla MRI , fluorine F 18 sodium fluoride PET/CT scan . After completion study , patient follow 4-6 month periodically week 52 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sodium Fluoride</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<mesh_term>Listerine</mesh_term>
	<criteria>History prior radical prostatectomy prostate cancer Two PSA value &gt; = 0.2 ng/mL least 4 week prostatectomy Patients start radiographic evaluation underwent CT scan and/or bone scan prior registration study able participate late registration provision , provide modern scan ( WB/axial MRI F18 NaF PET/CT ) complete within 8 week CT scan bone scan Patients know metastatic disease PSA recurrence verify elevated PSA discuss eligibility section Patients initiate androgen deprivation therapy systemic therapy ( chemotherapy , immunotherapy , target therapy ) PSA recurrence ; nutritional supplement use treatment PSA recurrence allow</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>